AOD-9604 in Mank — Fat Loss Peptide Research Guide
AOD-9604 research guide for Mank. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Mank trying to locate AOD-9604, the foundational reality is that this compound is distributed via specialist online vendors. This online-only market structure is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways no local retailer can match. What consistently distinguishes top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. The sections below cover what Mank researchers need to know about finding, evaluating, and storing AOD-9604 for research purposes.
Understanding AOD-9604 — Biology & Evidence
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Mank studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate AOD-9604 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at very low concentrations. Positive vendor signals beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. The dry lyophilised powder of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Mank
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no discount compensates for this missing data. Protocol documentation — recording exactly what was used, when, and how — is a research best practice for AOD-9604 that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
